About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 851267, 11 pages
http://dx.doi.org/10.1155/2013/851267
Research Article

Antihyperglycemic Effects of Short Term Resveratrol Supplementation in Type 2 Diabetic Patients

1Department of Endocrine and Metabolic Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr, University of Medical Sciences, Bushehr 7514763448, Iran
2Heart Failure Research Laboratory, Canadian Centre for Agri-Food Research in Health and Medicine, St. Boniface Research Centre, Winnipeg, MB, Canada R2H 2A6
3Agriculture and Agri-Food Canada, Winnipeg, MB, Canada R3T 2M9
4Department of Physiology, University of Manitoba, Winnipeg, MB, Canada R3E 0J9

Received 13 June 2013; Accepted 25 July 2013

Academic Editor: MinKyun Na

Copyright © 2013 Ali Movahed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. H. Herman and P. Zimmet, “Type 2 diabetes: an epidemic requiring global attention and urgent action,” Diabetes Care, vol. 35, pp. 943–944, 2012.
  2. D. W. Lam and D. LeRoith, “The worldwide diabetes epidemic,” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 19, no. 2, pp. 93–96, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, pp. 137–188, 2013.
  4. M. Stolar, “Glycemic control and complications in type 2 diabetes mellitus,” American Journal of Medicine, vol. 123, pp. S3–S11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. X. L. Louis, S. J. Thandapilly, S. K. MohanKumar et al., “Treatment with low-dose resveratrol reverses cardiac impairment in obese prone but not in obese resistant rats,” Journal of Nutritional Biochemistry, vol. 23, pp. 1163–1169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Lin and Z. Sun, “Current views on type 2 diabetes,” Journal of Endocrinology, vol. 204, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. J. Thandapilly, X. L. Louis, T. Yang et al., “Resveratrol prevents norepinephrine induced hypertrophy in adult rat cardiomyocytes, by activating NO-AMPK pathway,” European Journal of Pharmacology, vol. 668, no. 1-2, pp. 217–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. International Diabetes Federation, IDF Diabetes Atlas Update, International Diabetes Federation, Brussels, Belgium, 2012.
  9. A. Hussain, S. Vaaler, M. A. Sayeed, H. Mahtab, S. M. K. Ali, and A. K. A. Khan, “Type 2 diabetes and impaired fasting blood glucose in rural Bangladesh: a population-based study,” European Journal of Public Health, vol. 17, no. 3, pp. 291–296, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. S. Freeman, “The increasing epidemiology of diabetes and review of current treatment algorithms,” Journal of the American Osteopathic Association, vol. 110, no. 7, pp. eS2–eS6, 2010. View at Scopus
  11. F. Azizi, M. M. Gouya, P. Vazirian, P. Dolatshahi, and S. Habibian, “Screening for type 2 diabetes in the Iranian national programme: a preliminary report,” Eastern Mediterranean Health Journal, vol. 9, no. 5-6, pp. 1122–1127, 2003. View at Scopus
  12. A. A. Haghdoost, M. Rezazadeh-Kermani, B. Sadghirad, and H. R. Baradaran, “Prevalence of type 2 diabetes in the Islamic Republic of Iran: systematic review and meta-analysis,” Eastern Mediterranean Health Journal, vol. 15, no. 3, pp. 591–599, 2009. View at Scopus
  13. W. Yu, Y. Fu, and W. Wang, “Cellular and molecular effects of resveratrol in health and disease,” Journal of Cellular Biochemistry, vol. 113, no. 3, pp. 752–759, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Juhasz, B. Varga, R. Gesztelyi, A. Kemeny-Beke, J. Zsuga, and A. Tosaki, “Resveratrol: a multifunctional cytoprotective molecule,” Current Pharmaceutical Biotechnology, vol. 11, no. 8, pp. 810–818, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Juric, P. Wojciechowski, D. K. Das, and T. Netticadan, “Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol,” American Journal of Physiology, vol. 292, no. 5, pp. H2138–H2143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. J. Thandapilly, P. Wojciechowski, J. Behbahani et al., “Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure,” American Journal of Hypertension, vol. 23, no. 2, pp. 192–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Sharma, C. S. Misra, S. Arumugam et al., “Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes,” Phytotherapy Research, vol. 25, no. 1, pp. 67–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Ramadori, L. Gautron, T. Fujikawa, C. R. Vianna, J. K. Elmquist, and R. Coppari, “Central administration of resveratrol improves diet-induced diabetes,” Endocrinology, vol. 150, no. 12, pp. 5326–5333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Szkudelski and K. Szkudelska, “Anti-diabetic effects of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 34–39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. G. M. Do, U. J. Jung, H. J. Park et al., “Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice,” Molecular Nutrition & Food Research, vol. 56, pp. 1282–1291, 2012.
  21. J. K. Bhatt, S. Thomas, and M. J. Nanjan, “Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus,” Nutrition Research, vol. 32, pp. 537–541, 2012.
  22. P. Brasnyó, G. A. Molnár, M. Mohás, et al., “Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients,” British Journal of Nutrition, vol. 106, no. 3, pp. 383–389, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. P. Crandall, V. Oram, G. Trandafirescu et al., “Pilot study of resveratrol in older adults with impaired glucose tolerance,” The Journals of Gerontology A, vol. 67, pp. 1307–1312, 2012.
  24. S. Timmers, E. Konings, L. Bilet et al., “Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans,” Cell Metabolism, vol. 14, no. 5, pp. 612–622, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. M. M. Poulsen, P. F. Vestergaard, B. F. Clasen et al., “High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition,” Diabetes, vol. 62, no. 4, pp. 1186–1195, 2013.
  26. A. Bruckbauer and M. B. Zemel, “Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity,” Diabetes, Metabolic Syndrome and Obesity, vol. 6, pp. 93–102, 2013.
  27. C. A. Burtis and E. R. Ashwood, “Carbohydrates,” in Tietz Textbook of Clinical Chemistry, pp. 750–808, W.B Saunders, Philadelphia, Pa, USA, 1999.
  28. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Scopus
  29. J. Jeppsson, U. Kobold, J. Barr et al., “Approved IFCC reference method for the measurement of HbA1c in human blood,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 1, pp. 78–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Sapin, V. Le Galudec, F. Gasser, M. Pinget, and D. Grucker, “Elecsys insulin assay: free insulin determination and the absence of cross-reactivity with insulin lispro,” Clinical Chemistry, vol. 47, no. 3, pp. 602–605, 2001. View at Scopus
  31. D. R. Matthews, J. P. Hosker, and A. S. Rudenski, “Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man,” Diabetologia, vol. 28, no. 7, pp. 412–419, 1985. View at Scopus
  32. O. Vang, N. Ahmad, C. A. Baile et al., “What is new for an old molecule? Systematic review and recommendations on the use of resveratrol,” PLoS ONE, vol. 6, no. 6, Article ID e19881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. M. Smoliga, J. A. Baur, and H. A. Hausenblas, “Resveratrol and health—a comprehensive review of human clinical trials,” Molecular Nutrition and Food Research, vol. 55, no. 8, pp. 1129–1141, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Genovesi, P. Brambilla, M. Giussani et al., “Insulin resistance, prehypertension, hypertension and blood pressure values in paediatric age,” Journal of Hypertension, vol. 30, no. 2, pp. 327–335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. V. A. Brown, K. R. Patel, M. Viskaduraki et al., “Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis,” Cancer Research, vol. 70, no. 22, pp. 9003–9011, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Ghazanfari, A. A. Haghdoost, S. M. Alizadeh, J. Atapour, and F. Zolala, “A comparison of HbA1c and fasting blood sugar tests in general population,” International Journal of Preventive Medicine, vol. 1, no. 3, pp. 187–194, 2010. View at Scopus
  37. J. A. Hirst, A. J. Farmer, R. Ali, N. W. Roberts, and R. J. Stevens, “Quantifying the effect of metformin treatment and dose on glycemic control,” Diabetes Care, vol. 35, no. 2, pp. 446–454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–1495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Sone, S. Tanaka, S. Iimuro et al., “Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study,” Diabetes Care, vol. 35, pp. 1150–1157, 2012.
  40. S. Bonakdaran, S. Ebrahimzadeh, and S. H. Noghabi, “Cardiovascular disease and risk factors in patients with type 2 diabetes mellitus in Mashhad, Islamic Republic of Iran,” Eastern Mediterranean Health Journal, vol. 17, no. 9, pp. 640–646, 2011. View at Scopus
  41. MayoClinic, Niacin to Boost Your HDL, “Good”, Cholesterol, MayoClinic, Rochester, Minn, USA, 2011.
  42. B. Keidan, J. Hsia, and R. Katz, “Plasma lipids and antidiabetic agents: a brief overview,” British Journal of Diabetes and Vascular Disease, vol. 2, article 3, 2002.
  43. S. T. Brookes, E. Whitley, T. J. Peters, P. A. Mulheran, M. Egger, and G. D. Smith, “Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives,” Health Technology Assessment, vol. 5, no. 33, pp. 1–56, 2001. View at Scopus